Company Overview
agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc. and changed its name to agilon health, inc. in March 2021. The company was founded in 2016 and is based in Westerville, Ohio.
Why Investors Should Care
Revenue has grown at a 35.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Dec 2025 Revenue of $5.93B (-2.1% YoY); net profit $-391.35M.
- Trailing 12 Months Year-on-year growth — revenue -7.3%, earnings +301.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 35.4%, profit CAGR -89.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 35.43% |
| 1 Year: | -7.30% |
Compounded Profit Growth
| 5 Years: | -89.09% |
| 1 Year: | 301.00% |
Stock Price Performance
| 1 Year: | +117.97% |
| 6 Months: | +394.40% |
| 3 Months: | +466.85% |
| 1 Month: | +5.55% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)66.34 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 35.4% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Earnings shrank at -89.1% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AGL agilon health, inc. R2K | 122.61 | -5.43 | $2.05B | 0.00% | - | -109.59% | 35.43% | -89.09% |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 291.05M | 293.59M | 312.68M | 413.10M | 498.96M | 458.61M | 653.45M | 670.13M | 694.86M | 1.05B | 1.07B | 1.14B | 1.60B | 1.48B | 1.45B | - | 1.53B | 1.39B | 1.44B | 1.57B | 1.42B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.48B | 1.45B | 1.50B | 1.66B | 1.36B |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.72M | -52.43M | -67.65M | -90.67M | 65.02M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 72.83M | 63.60M | 63.63M | 67.07M | 61.02M |
| Operating Income | -5.83M | -1.25M | -9.84M | -12.12M | -298.36M | -35.60M | -743.00K | -21.05M | -29.52M | 417.00K | -28.96M | -39.29M | -7.18M | -43.34M | -133.51M | - | -22.11M | -116.03M | -131.27M | -157.74M | 4.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 6.70M | -95.42M | -101.27M | -178.87M | 38.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.51M | 1.57M | 1.84M | 1.72M | 1.81M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -1.69M | -104.31M | -110.54M | -187.56M | 29.94M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 196.00K | 62.00K | -331.00K | 1.32M | 28.00K |
| Net Income | -16.10M | -7.91M | -11.83M | -15.08M | -298.85M | -35.84M | 1.23M | -20.65M | -30.67M | 16.02M | -16.75M | -31.44M | -6.06M | -30.68M | -117.61M | - | 12.11M | -104.37M | -110.21M | -188.88M | 48.92M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.73 | -6.25 | -6.75 | -11.50 | 2.94 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 794.41M | 1.22B | 1.52B | 2.39B | 4.32B | 6.06B | 5.93B |
| Cost of Revenue | - | - | - | 2.28B | 4.25B | 6.06B | 6.09B |
| Gross Profit | - | - | - | 111.36M | 69.67M | 4.84M | -160.02M |
| Operating Expenses | - | - | - | 216.74M | 301.80M | 293.38M | 267.13M |
| Operating Income | -106.57M | -56.67M | -372.24M | -105.38M | -232.13M | -288.53M | -427.15M |
| EBITDA | - | - | - | -72.41M | -167.64M | -218.19M | -368.86M |
| Interest Expense | - | - | - | 4.48M | 6.66M | 6.18M | 6.64M |
| Pretax Income | - | - | - | -90.67M | -194.46M | -248.83M | -404.10M |
| Tax Provision | - | - | - | 1.64M | 791.00K | 1.45M | 1.25M |
| Net Income | -282.59M | -60.05M | -406.49M | -106.55M | -262.60M | -260.15M | -391.35M |
| Diluted EPS | - | - | - | -6.50 | -16.00 | -15.75 | -23.75 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 446.36M | - | 1.70B | 1.74B | 1.73B | 1.27B |
| Current Assets | - | - | - | - | 1.45B | 1.48B | 1.46B | 1.10B |
| Cash & Equivalents | - | - | 106.80M | - | 465.30M | 107.57M | 188.23M | 173.71M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 492.36M | 942.46M | 1.02B | 673.79M |
| Total Liabilities | - | - | 421.59M | - | 656.86M | 1.08B | 1.26B | 1.14B |
| Current Liabilities | - | - | 266.83M | - | 535.09M | 977.16M | 1.15B | 1.08B |
| Long Term Debt | - | - | 64.67M | - | 38.48M | 32.31M | 34.90M | 15.75M |
| Total Debt | - | - | - | - | 52.57M | 43.21M | 41.50M | 36.81M |
| Total Equity | 41.60M | -232.03M | -284.73M | - | 1.04B | 661.84M | 470.95M | 126.73M |
| Shares Outstanding | - | - | - | - | 16.50M | 16.26M | 16.49M | 16.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -103.86M | -53.20M | - | -130.81M | -156.20M | -57.78M | -105.76M |
| Investing Cash Flow | -5.06M | 22.07M | - | -444.39M | -44.02M | 139.89M | 88.61M |
| Financing Cash Flow | 176.30M | 24.62M | - | 28.06M | -193.13M | -2.58M | -2.99M |
| Capital Expenditure | -2.89M | -1.77M | - | -32.66M | -30.82M | -41.28M | -43.11M |
| Free Cash Flow | -106.75M | -54.98M | - | -163.47M | -187.01M | -99.06M | -148.87M |
| Net Change in Cash | - | - | - | -547.14M | -393.35M | 79.53M | -20.15M |
| Share Buybacks | - | 6.70M | - | - | 200.00M | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | 4.7% | 1.6% | 0.1% | -2.7% |
| Operating Margin % | -13.4% | -4.7% | -24.5% | -4.4% | -5.4% | -4.8% | -7.2% |
| Net Margin % | -35.6% | -4.9% | -26.7% | -4.5% | -6.1% | -4.3% | -6.6% |
| ROE % | 121.8% | 21.1% | - | -10.2% | -39.7% | -55.2% | -308.8% |
| ROCE % | - | -31.6% | - | -9.1% | -30.4% | -49.6% | -219.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AGL
Brookdale Senior Q2'26 Sneak Peek: Occupancy Volume Rises to 82.4%
BKD's Q2 weighted average occupancy rises to 82.4% as steady resident demand and RevPAR growth expectations set the stage for its upcoming earnings.
agilon health Reports ACO REACH Model Results for 2024 Performance Year
WESTERVILLE, Ohio, July 10, 2026--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organizations (ACOs) achieved $229 million in gros…
1 Momentum Stock on Our Buy List and 2 Facing Challenges
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.…
agilon health Sets Date to Report Second Quarter 2026 Financial Results
WESTERVILLE, Ohio, July 07, 2026--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 aft…
What's Making Tenet Healthcare Stock Stand Out Right Now?
THC is gaining on rising admissions, strong ambulatory care growth and earnings momentum. But can it sustain gains as expenses keep climbing?
How Investors Are Reacting To agilon health (AGL) Scrutiny On Value-Based Medicare Advantage Execution
In recent days, agilon health has been in focus as investors assess its value-based care platform for Medicare Advantage seniors, while CFO Jeffrey A. Schwaneke had 2,311 RSU shares withheld by the company to cover tax obligations, leaving …
AGL — Frequently Asked Questions
What is the current share price of agilon health, inc. (AGL)?
As of 2026-07-14 21:23 PDT, agilon health, inc. (AGL) trades at $122.61 on NYSE. Its 52-week range is $7.91 to $122.61.
What is the market capitalisation of AGL?
agilon health, inc. (AGL) has a market capitalisation of $2.05B on NYSE.
What is the P/E ratio of AGL?
AGL trades at a trailing price-to-earnings (P/E) ratio of -5.43. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 10.33.
What is the return on equity (ROE) of AGL?
AGL has a return on equity (ROE) of -109.59%.
Is AGL a good stock to buy?
This page provides a data-driven analysis of agilon health, inc. (AGL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.